医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NEC Corporation to Market SomaLogic’s SOMAscan™ Assay in Japan

2014年09月30日 AM12:45
このエントリーをはてなブックマークに追加


 

BOULDER, Colo.

SomaLogic, Inc. and NEC Corporation (TYO: 6701) announced today an agreement that gives NEC exclusive marketing rights in Japan for SomaLogic’s SOMAscan™ assay, which is built on SomaLogic’s proprietary SOMAmer® technology. Under the agreement, NEC will offer access to the SOMAscan assay to biopharmaceutical companies, food companies, and academic research centers for their research in Japan.

SomaLogic’s breakthrough SOMAscan proteomic assay efficiently, accurately, and rapidly identifies and quantifies 1,129 proteins across a wide range of concentrations in small volumes of multiple biological sample types. Compared to other current proteomic technologies, SomaLogic’s breadth and depth of coverage offers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.

This new collaboration expands on a 2010 agreement between NEC and SomaLogic to explore applications of SomaLogic’s technology in the life sciences and healthcare markets. Under the previous agreement, NEC developed the SomaSuite™ software tool, which facilitates the interpretation of the large data sets produced by the SOMAscan assay. The SomaSuite software will also be provided to Japanese SOMAscan assay clients under the new agreement.

Both of these agreements with SomaLogic reflect NEC’s growing emphasis on applying its deep computational expertise to become a world leader in providing novel healthcare solutions. For more information about NEC Corporation, visit its website at http://www.nec.com.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company’s mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140929006129/en/

CONTACT

SomaLogic
Fintan R. Steele, Ph.D.
+1 720-214-3080
fsteele@somalogic.com
Cell:
+1 617-816-9834

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer